<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f9d1354-08df-6a10-e063-6294a90a29bb"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20250305"/>
   <setId root="41b3c3a7-5fb8-4451-a96c-2bd02613c021"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="079637826"/>
            <name>Bionpharma Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="079637826"/>
                  <name>Bionpharma Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="002193829"/>
                        <name>Patheon Softgels Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-234" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-234" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="864148801"/>
                        <name>Steril-Gene Life Sciences Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-234" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69452-234" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f9d2dd5-d57b-824c-e063-6294a90ac8db"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250305"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69452-233" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PROGESTERONE</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>PROGESTERONE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LECITHIN, SOYBEAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROGESTERONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69452-233-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181128"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA200900" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181128"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">P;3</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69452-234" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PROGESTERONE</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>PROGESTERONE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LECITHIN, SOYBEAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROGESTERONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4G7DS2Q64Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69452-234-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20181128"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA200900" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20181128"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">P;4</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="2f9d1083-188f-0d45-e063-6394a90ab61d"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Disorders and Probable Dementia</content>
                  </paragraph>
                  <paragraph>Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                     </content> and 
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5">WARNINGS</linkHtml>
                     </content>
                     <content styleCode="bold">, </content>
                     <content styleCode="bold">
                        <linkHtml href="#Section_5.1">Cardiovascular disorders</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5.3">Probable dementia</linkHtml>
                     </content>
                     <content styleCode="bold">.</content>)

 </paragraph>
                  <paragraph>The Women's Health Initiative (WHI) estrogen plus progestin sub study reported increased risks of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5">WARNINGS</linkHtml>
                     </content>,
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5.1">Cardiovascular disorders</linkHtml>
                     </content>
                     <content styleCode="bold">.</content>)

 </paragraph>
                  <paragraph>The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5.3">WARNINGS, Probable dementia</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_6.11">PRECAUTIONS, Geriatric Use</linkHtml>
                     </content>
                     <content styleCode="bold">.</content>)

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Breast Cancer</content>
                  </paragraph>
                  <paragraph>The WHI estrogen plus progestin sub study also demonstrated an increased risk of invasive breast cancer. (See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_5.2">WARNINGS, Malignant neoplasms,</linkHtml>
                     </content>
                     <content styleCode="bold">
                        <linkHtml href="#Section_5.2">Breast Cancer.</linkHtml>
                     </content>)

 </paragraph>
                  <paragraph>In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.</paragraph>
                  <paragraph>Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</paragraph>
               </text>
               <effectiveTime value="20240314"/>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="2f9d1083-1890-0d45-e063-6394a90ab61d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Progesterone capsules contain micronized progesterone for oral administration. Progesterone has a molecular weight of 314.47 and a molecular formula of C
 
  <sub>21</sub>H
 
  <sub>30</sub>O
 
  <sub>2</sub>. Progesterone (pregn-4-ene-3, 20-dione) is a white or creamy white, odorless, crystalline powder practically insoluble in water, soluble in alcohol, acetone and dioxane and sparingly soluble in vegetable oils, stable in air, melting between 126° and 131°C. The structural formula is:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Progesterone is synthesized from a starting material from a plant source and is chemically identical to progesterone of human ovarian origin. Progesterone capsules are available in multiple strengths to afford dosage flexibility for optimum management. Progesterone capsules contain 100 mg or 200 mg micronized progesterone.</paragraph>
                  <paragraph>The inactive ingredients for progesterone capsules 100 mg include: ferric oxide yellow, gelatin, glycerin, lecithin, peanut oil, and titanium dioxide.</paragraph>
                  <paragraph>The inactive ingredients for progesterone capsules 200 mg include: gelatin, glycerin, lecithin, peanut oil, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="2f9d1083-1891-0d45-e063-6394a90ab61d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Progesterone capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. The oral bioavailability of progesterone is increased through micronization.</paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <section ID="Section_2.1">
                     <id root="2f9d1083-1892-0d45-e063-6394a90ab61d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <effectiveTime value="20240314"/>
                     <component>
                        <section ID="Section_2.1.1">
                           <id root="2f9d1083-1893-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">A. Absorption</content>
                           </title>
                           <text>
                              <paragraph>After oral administration of progesterone as a micronized soft-gelatin capsule formulation, maximum serum concentrations were attained within 3 hours. The absolute bioavailability of micronized progesterone is not known. Table 1 summarizes the mean pharmacokinetic parameters in postmenopausal women after five oral daily doses of progesterone capsules 100 mg as a micronized soft-gelatin capsule formulation.</paragraph>
                              <table cellspacing="0" cellpadding="0">
                                 <caption>TABLE 1. Pharmacokinetic Parameters of Progesterone Capsules</caption>
                                 <thead>
                                    <tr>
                                       <th rowspan="2" align="center" styleCode="Lrule Rrule" valign="top">Parameter</th>
                                       <th colspan="3" align="center" styleCode="Rrule" valign="top">Progesterone Capsules Daily Dose</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Lrule Rrule Toprule" valign="top">100 mg</th>
                                       <th align="center" styleCode="Rrule Toprule" valign="top">200 mg</th>
                                       <th align="center" styleCode="Rrule Toprule" valign="top">300 mg</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">C
    
     <sub>max</sub>(ng/mL)
   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">17.3 ± 21.9
    
     <footnote ID="L39506f88-5040-4f44-866d-6a73f5b406c1">Mean ± S.D.</footnote>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">38.1 ± 37.8</td>
                                       <td align="center" styleCode="Rrule" valign="top">60.6 ± 72.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">T
    
     <sub>max</sub>(hr)
   
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">1.5 ± 0.8</td>
                                       <td align="center" styleCode="Rrule" valign="top">2.3 ± 1.4</td>
                                       <td align="center" styleCode="Rrule" valign="top">1.7 ± 0.6</td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Lrule Rrule" valign="top">AUC (0-10) (ng × hr/mL)</td>
                                       <td align="center" styleCode="Rrule" valign="top">43.3 ± 30.8</td>
                                       <td align="center" styleCode="Rrule" valign="top">101.2 ± 66.0</td>
                                       <td align="center" styleCode="Rrule" valign="top">175.7 ± 170.3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of progesterone capsules 100 mg over the dose range 100 mg per day to 300 mg per day in postmenopausal women. Although doses greater than 300 mg per day were not studied in females, serum concentrations from a study in male volunteers appeared linear and dose proportional between 100 mg perday and 400 mg per day. The pharmacokinetic parameters in male volunteers were generally consistent with those seen in postmenopausal women.</paragraph>
                           </text>
                           <effectiveTime value="20240314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.2">
                           <id root="2f9d1083-1894-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">B. Distribution</content>
                           </title>
                           <text>
                              <paragraph>Progesterone is approximately 96 percent to 99 percent bound to serum proteins, primarily to serum albumin (50 percent to 54 percent) and transcortin (43 percent to 48 percent).</paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.3">
                           <id root="2f9d1083-1895-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">C. Metabolism</content>
                           </title>
                           <text>
                              <paragraph>Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites which are excreted in the bile may be deconjugated and may be further metabolized in the intestine via reduction, dehydroxylation, and epimerization.</paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.4">
                           <id root="2f9d1083-1896-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">D. Excretion</content>
                           </title>
                           <text>
                              <paragraph>The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and urine. Progesterone metabolites are eliminated mainly by the kidneys. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces.</paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.5">
                           <id root="2f9d1083-1897-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">E. Special Populations</content>
                           </title>
                           <text>
                              <paragraph>The pharmacokinetics of progesterone capsules have not been assessed in low body weight or obese patients.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="underline">Hepatic Insufficiency: </content>
                                 </content>The effect of hepatic impairment on the pharmacokinetics of progesterone capsules has not been studied.

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="underline">Renal Insufficiency:</content>
                                 </content>The effect of renal impairment on the pharmacokinetics of progesterone capsules has not been studied.

 </paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.6">
                           <id root="2f9d1083-1898-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">F. Food–Drug Interaction</content>
                           </title>
                           <text>
                              <paragraph>Concomitant food ingestion increased the bioavailability of progesterone capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg.</paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.7">
                           <id root="2f9d1083-1899-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">G. Drug Interactions</content>
                           </title>
                           <text>
                              <paragraph>The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC
 
  <sub>50</sub>&lt;0.1 M). Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the
 
  <content styleCode="italics">in vitro</content>findings is unknown.

 </paragraph>
                              <paragraph>Co-administration of conjugated estrogens and progesterone capsules to 29 postmenopausal women over a 12-day period resulted in an increase in total estrone concentrations (C
 
  <sub>max</sub>3.68 ng/mL to 4.93 ng/mL) and total equilin concentrations (C
 
  <sub>max</sub>2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17 estradiol concentrations (C
 
  <sub>max</sub>0.037 ng/mL to 0.030 ng/mL). The half-life of the conjugated estrogens was similar with co-administration of progesterone capsules. Table 2 summarizes the pharmacokinetic parameters.

 </paragraph>
                              <table cellspacing="0" cellpadding="0">
                                 <caption>TABLE 2. Mean (± S.D.) Pharmacokinetic Parameters for Estradiol, Estrone, and Equilin Following Co-administration of Conjugated Estrogens 0.625 mg and Progesterone Capsules 200 mg for 12 Days to Postmenopausal Women</caption>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <col width="10%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th styleCode="Lrule Rrule Toprule"/>
                                       <th colspan="3" align="center" styleCode="Lrule Rrule Toprule">Conjugated Estrogens</th>
                                       <th colspan="3" align="center" styleCode="Lrule Rrule Toprule">Conjugated Estrogens plus 
     <br/>  Progesterone Capsules
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">
                                          <content styleCode="bold">Drug</content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (ng/mL)
    
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">T
     
      <sub>max</sub>(hr)
    
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">AUC
     
      <sub>(0-24h)</sub>
                                             <br/>  (ng × h/mL)
    
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (ng/mL)
    
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">T
     
      <sub>max</sub>
                                             <br/>  (hr)
    
     </content>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">
                                          <content styleCode="bold">AUC
     
      <sub>(0-24h)</sub>
                                             <br/>  (ng × h/mL)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">Estradiol</td>
                                       <td align="center" styleCode="Rrule" valign="top">0.037 ± 
     <br/>  0.048
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">12.7 ± 
     <br/>  9.1
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">0.676 ± 
     <br/>  0.737
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">0.030 ± 
     <br/>  0.032
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">17.32 ± 
     <br/>  1.21
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">0.561 ± 0.572</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="center" styleCode="Lrule Rrule" valign="top">Estrone 
     <br/>  Total
    
     <footnote ID="L879ad6eb-23b2-422a-9316-b286e0f47b81">Total estrogens is the sum of conjugated and unconjugated estrogen.</footnote>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">3.68 ± 
     <br/>  1.55
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">10.6 ± 
     <br/>  6.8
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">61.3 ± 
     <br/>  26.36
    </td>
                                       <td align="center" styleCode="Rrule" valign="top">4.93 ± 2.07</td>
                                       <td align="center" styleCode="Rrule" valign="top">7.5 ± 3.8</td>
                                       <td align="center" styleCode="Rrule" valign="top">85.9 ± 41.2</td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Lrule Rrule" valign="top">Equilin 
     <br/>  Total
    
     <sup>1</sup>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">2.27 ± 0.95</td>
                                       <td align="center" styleCode="Rrule" valign="top">6.0 ± 4.0</td>
                                       <td align="center" styleCode="Rrule" valign="top">28.8 ± 13.0</td>
                                       <td align="center" styleCode="Rrule" valign="top">3.22 ± 1.13</td>
                                       <td align="center" styleCode="Rrule" valign="top">5.3 ± 2.6</td>
                                       <td align="center" styleCode="Rrule" valign="top">38.1 ± 20.2 </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="2f9d1083-189a-0d45-e063-6394a90ab61d"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>CLINICAL STUDIES</title>
                     <effectiveTime value="20240314"/>
                     <component>
                        <section ID="Section_2.2.1">
                           <id root="2f9d1083-189b-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Effects on the endometrium</content>
                           </title>
                           <text>
                              <paragraph>In a randomized, double-blind clinical trial, 358 postmenopausal women, each with an intact uterus, received treatment for up to 36 months. The treatment groups were: progesterone capsules at the dose of 200 mg per day for 12 days per 28-day cycle in combination with conjugated estrogens 0.625 mg/day (n=120); conjugated estrogens 0.625 mg/day only (n = 119); or placebo (n = 119). The subjects in all three treatment groups were primarily Caucasian women (87 percent or more of each group). The results for the incidence of endometrial hyperplasia in women receiving up to 3 years of treatment are shown in Table 3. A comparison of the progesterone capsules plus conjugated estrogens treatment group to the conjugated estrogens only group showed a significantly lower rate of hyperplasia (6 percent combination product versus 64 percent estrogen alone) in the progesterone capsules plus conjugated estrogens treatment group throughout 36 months of treatment.</paragraph>
                              <table>
                                 <caption>TABLE 3. Incidence of Endometrial Hyperplasia in Women Receiving 3 Years of Treatment</caption>
                                 <thead>
                                    <tr>
                                       <th align="left" styleCode="Lrule Rrule Toprule">Endometrial Diagnosis</th>
                                       <th colspan="6" align="center" styleCode="Lrule Rrule Toprule">Treatment Group</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Lrule Rrule Toprule"/>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">Conjugated Estrogens 0.625 mg + Progesterone Capsules 200 mg (cyclical)</th>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">Conjugated Estrogens 0.625 mg (alone)</th>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">Placebo</th>
                                    </tr>
                                    <tr>
                                       <th rowspan="2" align="center" styleCode="Lrule Rrule Toprule"/>
                                       <th align="center" styleCode="Lrule Rrule Toprule">Number of patients</th>
                                       <th align="center" styleCode="Lrule Rrule Toprule">% of patients</th>
                                       <th align="center" styleCode="Lrule Rrule Toprule">Number of patients</th>
                                       <th align="center" styleCode="Lrule Rrule Toprule">% of patients</th>
                                       <th align="center" styleCode="Lrule Rrule Toprule">Number of patients</th>
                                       <th align="center" styleCode="Lrule Rrule Toprule">% of patients</th>
                                    </tr>
                                    <tr>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">n = 117</th>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">n = 115</th>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule Toprule">n = 116</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td styleCode="Lrule Rrule" valign="top">HYPERPLASIA
    
     <footnote ID="L80b843dc-51f5-4ce6-9ae0-3f1db171f92a">Most advanced result to least advanced result:</footnote>
                                       </td>
                                       <td align="center" styleCode="Rrule" valign="top">7</td>
                                       <td align="center" styleCode="Rrule" valign="top">6</td>
                                       <td align="center" styleCode="Rrule" valign="top">74</td>
                                       <td align="center" styleCode="Rrule" valign="top">64</td>
                                       <td align="center" styleCode="Rrule" valign="top">3</td>
                                       <td align="center" styleCode="Rrule" valign="top">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Adenocarcinoma</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Atypical hyperplasia</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                       <td align="center" styleCode="Rrule" valign="top">14</td>
                                       <td align="center" styleCode="Rrule" valign="top">12</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="top">Complex hyperplasia</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">0</td>
                                       <td align="center" styleCode="Rrule" valign="top">27</td>
                                       <td align="center" styleCode="Rrule" valign="top">23</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" valign="top">Simple hyperplasia</td>
                                       <td align="center" styleCode="Rrule" valign="top">6</td>
                                       <td align="center" styleCode="Rrule" valign="top">5</td>
                                       <td align="center" styleCode="Rrule" valign="top">33</td>
                                       <td align="center" styleCode="Rrule" valign="top">29</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                       <td align="center" styleCode="Rrule" valign="top">1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Adenocarcinoma &gt; atypical hyperplasia &gt; complex hyperplasia &gt; simple hyperplasia</paragraph>
                              <paragraph>The times to diagnosis of endometrial hyperplasia over 36 months of treatment are shown in Figure 1. This figure illustrates graphically that the proportion of patients with hyperplasia was significantly greater for the conjugated estrogens group (64 percent) compared to the conjugated estrogens plus progesterone capsules group (6 percent).</paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 1. Time to Hyperplasia in Women Receiving up to 36 Months of Treatment</content>
                              </paragraph>
                              <paragraph>The discontinuation rates due to hyperplasia over the 36 months of treatment are as shown in Table 4. For any degree of hyperplasia, the discontinuation rate for patients who received conjugated estrogens plus progesterone capsules was similar to that of the placebo only group, while the discontinuation rate for patients who received conjugated estrogens alone was significantly higher. Women who permanently discontinued treatment due to hyperplasia were similar in demographics to the overall study population.</paragraph>
                              <table>
                                 <caption>TABLE 4. Discontinuation Rate Due to Hyperplasia Over 36 Months of Treatment</caption>
                                 <thead>
                                    <tr>
                                       <th rowspan="3">Most Advanced 
     <br/>  Biopsy Result Through 36 Months 
     <br/>  of Treatment
    </th>
                                       <th colspan="6">Treatment Group</th>
                                    </tr>
                                    <tr>
                                       <th colspan="2">Conjugated Estrogens + Progesterone Capsules (cyclical)</th>
                                       <th colspan="2">Conjugated Estrogens (alone)</th>
                                       <th colspan="2">Placebo</th>
                                    </tr>
                                    <tr>
                                       <th colspan="2">n = 120</th>
                                       <th colspan="2">n = 119</th>
                                       <th colspan="2">n = 119</th>
                                    </tr>
                                    <tr>
                                       <th/>
                                       <th>Number of 
     <br/>  patients
    </th>
                                       <th>% of 
     <br/>  patients
    </th>
                                       <th>Number of 
     <br/>  patients
    </th>
                                       <th>% of 
     <br/>  patients
    </th>
                                       <th>Number of 
     <br/>  patients
    </th>
                                       <th>% of 
     <br/>  patients
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td valign="top">Adenocarcinoma</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td valign="top">Atypical hyperplasia</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">10</td>
                                       <td align="center" valign="top">8</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td valign="top">Complex hyperplasia</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">21</td>
                                       <td align="center" valign="top">18</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">1</td>
                                    </tr>
                                    <tr>
                                       <td valign="top">Simple hyperplasia</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">1</td>
                                       <td align="center" valign="top">13</td>
                                       <td align="center" valign="top">11</td>
                                       <td align="center" valign="top">0</td>
                                       <td align="center" valign="top">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20240314"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>graph1</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="figure01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.2">
                           <id root="2f9d1083-189c-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Effects on secondary amenorrhea</content>
                           </title>
                           <text>
                              <paragraph>In a single-center, randomized, double-blind clinical study that included premenopausal women with secondary amenorrhea for at least 90 days, administration of 10 days of progesterone capsules therapy resulted in 80 percent of women experiencing withdrawal bleeding within 7 days of the last dose of progesterone capsules, 300 mg per day (n = 20), compared to 10 percent of women experiencing withdrawal bleeding in the placebo group (n = 21).</paragraph>
                              <paragraph>In a multicentre, parallel-group, open label, postmarketing dosing study that included premenopausal women with secondary amenorrhea for at least 90 days, administration of 10 days of progesterone capsules during two 28-day treatment cycles, 300 mg per day (n = 107) or 400 mg per day (n = 99), resulted in 73.8 percent and 76.8 percent of women, respectively, experiencing withdrawal bleeding.</paragraph>
                              <paragraph>The rate of secretory transformation was evaluated in a multicentre, randomized, double-blind clinical study in estrogen-primed postmenopausal women. Progesterone capsules administered orally for 10 days at 400 mg per day (n = 22) induced complete secretory changes in the endometrium in 45 percent of women compared to 0 percent in the placebo group (n = 23).</paragraph>
                              <paragraph>A second multicentre, parallel-group, open label postmarketing dosing study in premenopausal women with secondary amenorrhea for at least 90 days also evaluated the rate of secretory transformation. All subjects received daily oral conjugated estrogens over 3 consecutive 28-day treatment cycles and progesterone capsules, 300 mg per day (n = 107) or 400 mg per day (n = 99) for 10 days of each treatment cycle. The rate of complete secretory transformation was 21.5 percent and 28.3 percent, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.3">
                           <id root="2f9d1083-189d-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Women's Health Initiative Studies</content>
                           </title>
                           <text>
                              <paragraph>The Women's Health Initiative (WHI) enrolled approximately 27,000 predominantly healthy postmenopausal women in two sub studies to assess the risks and benefits of daily oral conjugated estrogens (CE) [0.625 mg]-alone or in combination with medroxyprogesterone acetate (MPA) [2.5 mg] compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease [(CHD) defined as nonfatal myocardial infarction (MI), silent MI and CHD death], with invasive breast cancer as the primary adverse outcome. A "global index" included the earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary embolism (PE), endometrial cancer (only in the CE plus MPA sub study), colorectal cancer, hip fracture, or death due to other cause. These sub studies did not evaluate the effects of CE-alone or CE plus MPA on menopausal symptoms.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">WHI Estrogen Plus Progestin Sub study</content>
                              </paragraph>
                              <paragraph>The WHI estrogen plus progestin sub study was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the "global index". The absolute excess risk of events in the "global index" was 19 per 10,000 women-years.</paragraph>
                              <paragraph>For those outcomes included in the WHI "global index" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.</paragraph>
                              <paragraph>Results of the estrogen plus progestin sub study, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 5. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</paragraph>
                              <table width="100%">
                                 <caption>TABLE 5. Relative and Absolute Risk Seen in the Estrogen Plus Progestin Sub study of WHI at an Average of 5.6 Years
  
   <footnote ID="L716eddba-ca7b-4670-a4d3-17f56bb0361a">Results are based on centrally adjudicated data.</footnote>
                                    <footnote ID="Ldc6a909d-6eff-4f74-a580-c16e3726d98e">Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</footnote>
                                 </caption>
                                 <tbody>
                                    <tr>
                                       <td align="left">
                                          <content styleCode="bold">Event</content>
                                       </td>
                                       <td align="center">
                                          <content styleCode="bold">Relative Risk CE/MPA versus Placebo (95% nCI
     
      <footnote ID="L511e1c78-b51e-4541-805b-a558c4160085">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)
    
     </content>
                                       </td>
                                       <td>
                                          <paragraph>
                                             <content styleCode="bold">CE/MPA</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">n = 8,506</content>
                                          </paragraph>
                                       </td>
                                       <td align="center">
                                          <paragraph>
                                             <content styleCode="bold">Placebo</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="bold">n = 8,102</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td/>
                                       <td/>
                                       <td colspan="2" align="center">
                                          <content styleCode="bold">Absolute Risk per 10,000 Women-Years</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td> CHD events</td>
                                       <td align="center"> 1.23 (0.99 to 1.53)</td>
                                       <td align="center"> 41</td>
                                       <td align="center"> 34</td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <content styleCode="italics">     Non-fatal MI</content>
                                       </td>
                                       <td align="center"> 1.28 (1.00 to 1.63)</td>
                                       <td align="center"> 31</td>
                                       <td align="center"> 25</td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <content styleCode="italics">     CHD death</content>
                                       </td>
                                       <td align="center"> 1.10 (0.70 to 1.75)</td>
                                       <td align="center"> 8</td>
                                       <td align="center"> 8</td>
                                    </tr>
                                    <tr>
                                       <td> All stroke</td>
                                       <td align="center"> 1.31 (1.03 to 1.88)</td>
                                       <td align="center"> 33</td>
                                       <td align="center"> 25</td>
                                    </tr>
                                    <tr>
                                       <td>     Ischemic stroke</td>
                                       <td align="center"> 1.44 (1.09 to 1.90)</td>
                                       <td align="center"> 26</td>
                                       <td align="center"> 18</td>
                                    </tr>
                                    <tr>
                                       <td> Deep vein thrombosis 
    
     <footnote ID="La142448d-f747-40df-802d-7de07a0b6fb1">Not included in Global Index.</footnote>
                                       </td>
                                       <td align="center"> 1.95 (1.43 to 2.67)</td>
                                       <td align="center"> 26</td>
                                       <td align="center"> 13</td>
                                    </tr>
                                    <tr>
                                       <td> Pulmonary embolism</td>
                                       <td align="center"> 2.13 (1.45 to 3.11)</td>
                                       <td align="center"> 18</td>
                                       <td align="center"> 8</td>
                                    </tr>
                                    <tr>
                                       <td> Invasive breast cancer 
    
     <footnote ID="L565edcd7-7aa8-4df5-8df2-c0036648c5da">Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.</footnote>
                                       </td>
                                       <td align="center"> 1.24 (1.01 to 1.54)</td>
                                       <td align="center"> 41</td>
                                       <td align="center"> 33</td>
                                    </tr>
                                    <tr>
                                       <td> Colorectal cancer</td>
                                       <td align="center"> 0.61 (0.42 to 0.87)</td>
                                       <td align="center"> 10</td>
                                       <td align="center"> 16</td>
                                    </tr>
                                    <tr>
                                       <td> Endometrial cancer
    
     <sup>§</sup>
                                       </td>
                                       <td align="center"> 0.81 (0.48 to 1.36)</td>
                                       <td align="center"> 6</td>
                                       <td align="center"> 7</td>
                                    </tr>
                                    <tr>
                                       <td> Cervical cancer
    
     <sup>§</sup>
                                       </td>
                                       <td align="center"> 1.44 (0.47 to 4.42)</td>
                                       <td align="center"> 2</td>
                                       <td align="center"> 1</td>
                                    </tr>
                                    <tr>
                                       <td> Hip fracture</td>
                                       <td align="center"> 0.67 (0.47 to 0.96)</td>
                                       <td align="center"> 11</td>
                                       <td align="center"> 16</td>
                                    </tr>
                                    <tr>
                                       <td> Vertebral fractures
    
     <sup>§</sup>
                                       </td>
                                       <td align="center"> 0.65 (0.46 to 0.92)</td>
                                       <td align="center"> 11</td>
                                       <td align="center"> 17</td>
                                    </tr>
                                    <tr>
                                       <td> Lower arm/wrist fractures
    
     <sup>§</sup>
                                       </td>
                                       <td align="center"> 0.71 (0.59 to 0.85)</td>
                                       <td align="center"> 44</td>
                                       <td align="center"> 62</td>
                                    </tr>
                                    <tr>
                                       <td> Total fractures
    
     <sup>§</sup>
                                       </td>
                                       <td align="center"> 0.76 (0.69 to 0.83)</td>
                                       <td align="center"> 152</td>
                                       <td align="center"> 199</td>
                                    </tr>
                                    <tr>
                                       <td> Overall mortality 
    
     <footnote ID="L9e3395d7-8755-499f-9a66-d8d2c97c8c8c">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote>
                                       </td>
                                       <td align="center"> 1.00 (0.83 to 1.19)</td>
                                       <td align="center"> 52</td>
                                       <td align="center"> 52</td>
                                    </tr>
                                    <tr>
                                       <td> Global Index 
    
     <footnote ID="L5418e4fe-8be7-4212-8580-1ceb5716a1f9">A subset of the events was combined in a global index defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.</footnote>
                                       </td>
                                       <td align="center"> 1.13 (1.02 to 1.25)</td>
                                       <td align="center"> 184</td>
                                       <td align="center"> 165</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin sub study stratified for age showed in women 50 years to 59 years of age a non-significant trend toward reducing risk of overall mortality [hazard ratio (HR) 0.69 (95 percent CI, 0.44 to  1.07)].</paragraph>
                           </text>
                           <effectiveTime value="20240314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.4">
                           <id root="2f9d1083-189e-0d45-e063-6394a90ab61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Women's Health Initiative Memory Study</content>
                           </title>
                           <text>
                              <paragraph>The estrogen plus progestin Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 years to 69 years of age; 35 percent were 70 years to 74 years of age; and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo.</paragraph>
                              <paragraph>After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21 to 3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed type (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 years to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women. (See
 
  <content styleCode="bold">
                                    <linkHtml href="#Section_5">WARNINGS</linkHtml>
                                 </content>,
 
  <content styleCode="bold">
                                    <linkHtml href="#Section_5.3">Probable dementia</linkHtml>
                                 </content>and
 
  <content styleCode="bold">
                                    <linkHtml href="#Section_6.11">PRECAUTIONS, Geriatric Use</linkHtml>
                                 </content>.)

 </paragraph>
                           </text>
                           <effectiveTime value="20240313"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="2f9d1083-189f-0d45-e063-6394a90ab61d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.</paragraph>
               </text>
               <effectiveTime value="20240313"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="2f9d1083-18a0-0d45-e063-6394a90ab61d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Progesterone capsules should not be used in women with any of the following conditions:</paragraph>
                  <list listType="ordered" styleCode="Arabic">
                     <item>
                        <content styleCode="bold">Progesterone capsules should not be used in patients with known hypersensitivity to its ingredients. Progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts.</content>
                     </item>
                     <item>Undiagnosed abnormal genital bleeding.</item>
                     <item>Known, suspected, or history of breast cancer.</item>
                     <item>Active deep vein thrombosis, pulmonary embolism or history of these conditions.</item>
                     <item>Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions.</item>
                     <item>Known liver dysfunction or disease.</item>
                     <item>Known or suspected pregnancy.</item>
                  </list>
               </text>
               <effectiveTime value="20240313"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="2f9d1083-18a1-0d45-e063-6394a90ab61d"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_0">BOXED WARNING</linkHtml>.
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240313"/>
               <component>
                  <section ID="Section_5.1">
                     <id root="2f9d1083-18a2-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1. Cardiovascular Disorders</title>
                     <text>
                        <paragraph>An increased risk of pulmonary embolism, deep vein thrombosis (DVT), stroke, and myocardial infarction has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with progestin therapy should be discontinued immediately.</paragraph>
                        <paragraph>Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (for example, personal history or family history of venous thromboembolism [VTE], obesity, and systemic lupus erythematosus) should be managed appropriately.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">a. Stroke</content>
                           </content>
                        </paragraph>
                        <paragraph>In the Women’s Health Initiative (WHI) estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 years to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years). The increase in risk was demonstrated after the first year and persisted. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>.) Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">b. Coronary Heart Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal myocardial infarction [MI], silent MI, or CHD death) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). An increase in relative risk was demonstrated in year 1 and a trend toward decreasing relative risk was reported in years 2 through 5. (See 
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>.)

 </paragraph>
                        <paragraph>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">c. Venous Thromboembolism</content>
                           </content>
                        </paragraph>
                        <paragraph>In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and pulmonary embolism [PE]) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>.) Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

 </paragraph>
                        <paragraph>If feasible, estrogens with progestins should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="2f9d1083-18a3-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2. Malignant Neoplasms</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">a. Breast Cancer</content>
                           </content>
                        </paragraph>
                        <paragraph>The WHI substudy of daily CE (0.625 mg)- alone provided information about breast cancer in estrogen‑alone users. In the WHI estrogen-alone substudy, after an average of follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] compared to placebo (see 
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>). In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for estrogen plus progestin compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>
                           <content styleCode="bold">.</content>)

 </paragraph>
                        <paragraph>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to &gt; 10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</paragraph>
                        <paragraph>The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">b. Endometrial Cancer</content>
                           </content>
                        </paragraph>
                        <paragraph>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 times to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with the use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15-fold to 24-fold for 5 years to 10 years or more and this risk has been shown to persist for at least 8 years to 15 years after estrogen therapy is discontinued.</paragraph>
                        <paragraph>Clinical surveillance of all women using estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">c. Ovarian Cancer</content>
                           </content>
                        </paragraph>
                        <paragraph>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent nCI, 0.77 to 3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies and some report no association.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="2f9d1083-18a4-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>3. Probable Dementia</title>
                     <text>
                        <paragraph>In the estrogen plus progestin Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, a population of 4,532 postmenopausal women 65 years to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.</paragraph>
                        <paragraph>In the WHIMS estrogen plus progestin ancillary study, after an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for estrogen plus progestin versus placebo was 2.05 (95 percent CI, 1.21 to  3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>and
 
  <content styleCode="bold">
                              <linkHtml href="#Section_6.11">PRECAUTIONS, Geriatric Use</linkHtml>
                           </content>.)

 </paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="2f9d1083-18a5-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4. Vision Abnormalities</title>
                     <text>
                        <paragraph>Retinal vascular thrombosis has been reported in patients receiving estrogen. Discontinue estrogen plus progestin therapy pending examination if there is sudden partial or complete loss of vision, or if there is a sudden onset of proptosis, diplopia or migraine. If examination reveals papilledema or retinal vascular lesions, estrogen plus progestin therapy should be permanently discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="2f9d1083-18a6-0d45-e063-6394a90ab61d"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20240313"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="2f9d1083-18a7-0d45-e063-6394a90ab61d"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>A. General</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">1. Addition of a progestin when a woman has not had a hysterectomy</content>
                        </paragraph>
                        <paragraph>Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.</paragraph>
                        <paragraph>There are, however, possible risks that may be associated with the use of progestins with estrogens compared with estrogen-alone regimens. These include an increased risk of breast cancer.</paragraph>
                        <paragraph>
                           <content styleCode="bold">2. Fluid Retention</content>
                        </paragraph>
                        <paragraph>Progesterone may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation.</paragraph>
                        <paragraph>
                           <content styleCode="bold">3. Dizziness and Drowsiness</content>
                        </paragraph>
                        <paragraph>Progesterone capsules may cause transient dizziness and drowsiness and should be used with caution when driving a motor vehicle or operating machinery. Progesterone capsules should be taken as a single daily dose at bedtime.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="2f9d1083-18a8-0d45-e063-6394a90ab61d"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>B. Patient Information</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">General: This product contains peanut oil and should not be used if you are allergic to peanuts.</content>
                        </paragraph>
                        <paragraph>Physicians are advised to discuss the contents of the Patient Information leaflet with patients for whom they prescribe progesterone capsules.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.3">
                     <id root="2f9d1083-18a9-0d45-e063-6394a90ab61d"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>C. Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>The following laboratory results may be altered by the use of estrogen plus progestin therapy:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Increased sulfobromophthalein retention and other hepatic function tests.</item>
                           <item>Coagulation tests: increase in prothrombin factors VII, VIII, IX and X.</item>
                           <item>Pregnanediol determination.</item>
                           <item>Thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T3
  
   <sub/>uptake values.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="2f9d1083-18aa-0d45-e063-6394a90ab61d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>D. Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Progesterone has not been tested for carcinogenicity in animals by the oral route of administration. When implanted into female mice, progesterone produced mammary carcinomas, ovarian granulosa cell tumors and endometrial stromal sarcomas. In dogs, long-term intramuscular injections produced nodular hyperplasia and benign and malignant mammary tumors. Subcutaneous or intramuscular injections of progesterone decreased the latency period and increased the incidence of mammary tumors in rats previously treated with a chemical carcinogen.</paragraph>
                        <paragraph>Progesterone did not show evidence of genotoxicity in
 
  <content styleCode="italics">in vitro</content>studies for point mutations or for chromosomal damage.
 
  <content styleCode="italics">In vivo </content>studies for chromosome damage have yielded positive results in mice at oral doses of 1,000 mg/kg and 2,000 mg/kg. Exogenously administered progesterone has been shown to inhibit ovulation in a number of species and it is expected that high doses given for an extended duration would impair fertility until the cessation of treatment.

 </paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="2f9d1083-18ab-0d45-e063-6394a90ab61d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>E. Pregnancy</title>
                     <text>
                        <paragraph>Progesterone capsules should not be used during pregnancy. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_4">CONTRAINDICATIONS</linkHtml>
                           </content>.)

 </paragraph>
                        <paragraph>Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monkeys at doses approximately the human dose, all based on body surface area, and have revealed little or no evidence of impaired fertility or harm to the fetus due to progesterone.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="2f9d1083-18ac-0d45-e063-6394a90ab61d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>F. Nursing Women</title>
                     <text>
                        <paragraph>Detectable amounts of progestin have been identified in the milk of nursing women receiving progestins. Caution should be exercised when progesterone capsules are administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20181128"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="2f9d1083-18ad-0d45-e063-6394a90ab61d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>G. Pediatric Use</title>
                     <text>
                        <paragraph>Progesterone capsules are not indicated in children. Clinical studies have not been conducted in the pediatric population.</paragraph>
                     </text>
                     <effectiveTime value="20181128"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.11">
                     <id root="2f9d1083-18ae-0d45-e063-6394a90ab61d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>H. Geriatric Use</title>
                     <text>
                        <paragraph>There have not been sufficient numbers of geriatric women involved in clinical studies utilizing progesterone capsules to determine whether those over 65 years of age differ from younger subjects in their response to progesterone capsules.</paragraph>
                        <paragraph>
                           <content styleCode="italics">The Women’s Health Initiative Study</content>
                        </paragraph>
                        <paragraph>In the Women’s Health Initiative (WHI) estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>and 
 
  <content styleCode="bold">
                              <linkHtml href="#Section_5">WARNINGS</linkHtml>,
  
   <linkHtml href="#Section_5.1">Cardiovascular Disorders</linkHtml> and
  
   <linkHtml href="#Section_5.2">Malignant Neoplasms</linkHtml>.)
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">The Women’s Health Initiative Memory Study</content>
                        </paragraph>
                        <paragraph>In the Women’s Health Initiative Memory Study (WHIMS) of postmenopausal women 65 years to 79 years of age, there was an increased risk of developing probable dementia in the estrogen plus progestin ancillary study when compared to placebo. (See
 
  <content styleCode="bold">
                              <linkHtml href="#Section_2.2">CLINICAL STUDIES</linkHtml>
                           </content>and
 
  <content styleCode="bold">
                              <linkHtml href="#Section_5.3">WARNINGS, Probable Dementia</linkHtml>
                           </content>.)

 </paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="2f9d1083-18af-0d45-e063-6394a90ab61d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_0">BOXED WARNING</linkHtml>,
  
   <linkHtml href="#Section_5">WARNINGS</linkHtml>
                     </content> and
 
  <content styleCode="bold">
                        <linkHtml href="#Section_6">PRECAUTIONS.</linkHtml>
                     </content>
                  </paragraph>
                  <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                  <paragraph>In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of progesterone capsules on the endometrium was studied in a total of 875 postmenopausal women. Table 6 lists adverse reactions greater than or equal to 2 percent of women who received cyclic progesterone capsules 200 mg daily (12 days per calendar month cycle) with 0.625 mg conjugated estrogens or placebo.</paragraph>
                  <table cellspacing="0" cellpadding="0">
                     <caption>TABLE 6. Adverse Reactions (≥2%) Reported in an 875 Patient Placebo-Controlled Trial in Postmenopausal Women Over a 3-Year Period [Percentage (%) of Patients Reporting]</caption>
                     <thead>
                        <tr>
                           <th rowspan="2" styleCode="Lrule Rrule" valign="top"/>
                           <th align="center" styleCode="Rrule" valign="top">Progesterone Capsules 200 mg with Conjugated Estrogens 
     <br/>  0.625 mg
    </th>
                           <th align="center" styleCode="Rrule" valign="top">Placebo</th>
                        </tr>
                        <tr>
                           <th align="center" styleCode="Lrule Rrule Toprule" valign="top">(n = 178)</th>
                           <th align="center" styleCode="Rrule Toprule" valign="top">(n = 174)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td styleCode="Lrule Rrule" valign="top">Headache</td>
                           <td align="center" styleCode="Rrule" valign="top">31</td>
                           <td align="center" styleCode="Rrule" valign="top">27</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Breast Tenderness</td>
                           <td align="center" styleCode="Rrule" valign="top">27</td>
                           <td align="center" styleCode="Rrule" valign="top">6</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Joint Pain</td>
                           <td align="center" styleCode="Rrule" valign="top">20</td>
                           <td align="center" styleCode="Rrule" valign="top">29</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Lrule Rrule" valign="top">Depression</td>
                           <td align="center" styleCode="Rrule" valign="top">19</td>
                           <td align="center" styleCode="Rrule" valign="top">12</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Dizziness</td>
                           <td align="center" styleCode="Rrule" valign="top">15</td>
                           <td align="center" styleCode="Rrule" valign="top">9</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Abdominal Bloating</td>
                           <td align="center" styleCode="Rrule" valign="top">12</td>
                           <td align="center" styleCode="Rrule" valign="top">5</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Hot Flashes</td>
                           <td align="center" styleCode="Rrule" valign="top">11</td>
                           <td align="center" styleCode="Rrule" valign="top">35</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Urinary Problems</td>
                           <td align="center" styleCode="Rrule" valign="top">11</td>
                           <td align="center" styleCode="Rrule" valign="top">9</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Abdominal Pain</td>
                           <td align="center" styleCode="Rrule" valign="top">10</td>
                           <td align="center" styleCode="Rrule" valign="top">10</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Lrule Rrule" valign="top">Vaginal Discharge</td>
                           <td align="center" styleCode="Rrule" valign="top">10</td>
                           <td align="center" styleCode="Rrule" valign="top">3</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Nausea / Vomiting</td>
                           <td align="center" styleCode="Rrule" valign="top">8</td>
                           <td align="center" styleCode="Rrule" valign="top">7</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Worry</td>
                           <td align="center" styleCode="Rrule" valign="top">8</td>
                           <td align="center" styleCode="Rrule" valign="top">4</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Chest Pain</td>
                           <td align="center" styleCode="Rrule" valign="top">7</td>
                           <td align="center" styleCode="Rrule" valign="top">5</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Diarrhea</td>
                           <td align="center" styleCode="Rrule" valign="top">7</td>
                           <td align="center" styleCode="Rrule" valign="top">4</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Night Sweats</td>
                           <td align="center" styleCode="Rrule" valign="top">7</td>
                           <td align="center" styleCode="Rrule" valign="top">17</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Lrule Rrule" valign="top">Breast Pain</td>
                           <td align="center" styleCode="Rrule" valign="top">6</td>
                           <td align="center" styleCode="Rrule" valign="top">2</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Swelling of Hands and Feet</td>
                           <td align="center" styleCode="Rrule" valign="top">6</td>
                           <td align="center" styleCode="Rrule" valign="top">9</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Lrule Rrule" valign="top">Vaginal Dryness</td>
                           <td align="center" styleCode="Rrule" valign="top">6</td>
                           <td align="center" styleCode="Rrule" valign="top">10</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Constipation</td>
                           <td align="center" styleCode="Rrule" valign="top">3</td>
                           <td align="center" styleCode="Rrule" valign="top">2</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Breast Carcinoma</td>
                           <td align="center" styleCode="Rrule" valign="top">2</td>
                           <td align="center" styleCode="Rrule" valign="top">&lt;1</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Breast Excisional Biopsy</td>
                           <td align="center" styleCode="Rrule" valign="top">2</td>
                           <td align="center" styleCode="Rrule" valign="top">&lt;1</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">Cholecystectomy</td>
                           <td align="center" styleCode="Rrule" valign="top">2</td>
                           <td align="center" styleCode="Rrule" valign="top">&lt;1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20240313"/>
               <component>
                  <section ID="Section_7.1">
                     <id root="2f9d1083-18b0-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Effects on Secondary Amenorrhea</title>
                     <text>
                        <paragraph>﻿﻿In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of progesterone capsules on secondary amenorrhea was studied in 49 estrogen-primed postmenopausal women. Table 7 lists adverse reactions greater than or equal to 5 percent of women who received progesterone capsules or placebo.</paragraph>
                        <table width="100%">
                           <caption>TABLE 7. Adverse Reactions (≥ 5%) Reported in Patients Using 400 mg/day in a Placebo-Controlled Trial in Estrogen-Primed Postmenopausal Women </caption>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold"> Adverse Experience</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold"> Progesterone Capsules 400 mg</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold"> Placebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center"/>
                                 <td align="center">
                                    <content styleCode="bold"> n = 25</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold"> n = 24</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td colspan="2" align="center">
                                    <content styleCode="bold"> Percentage (%) of Patients</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Fatigue</td>
                                 <td align="center">8</td>
                                 <td align="center">4</td>
                              </tr>
                              <tr>
                                 <td> Headache</td>
                                 <td align="center">16</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td> Dizziness</td>
                                 <td align="center">24</td>
                                 <td align="center">4</td>
                              </tr>
                              <tr>
                                 <td> Abdominal Distention (Bloating)</td>
                                 <td align="center">8</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td> Abdominal Pain (Cramping)</td>
                                 <td align="center">20</td>
                                 <td align="center">13</td>
                              </tr>
                              <tr>
                                 <td> Diarrhea</td>
                                 <td align="center">8</td>
                                 <td align="center">4</td>
                              </tr>
                              <tr>
                                 <td> Nausea</td>
                                 <td align="center">8</td>
                                 <td align="center">0</td>
                              </tr>
                              <tr>
                                 <td> Back Pain</td>
                                 <td align="center">8</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td> Musculoskeletal Pain</td>
                                 <td align="center">12</td>
                                 <td align="center">4</td>
                              </tr>
                              <tr>
                                 <td> Irritability</td>
                                 <td align="center">8</td>
                                 <td align="center">4</td>
                              </tr>
                              <tr>
                                 <td> Breast Pain</td>
                                 <td align="center">16</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td> Infection Viral</td>
                                 <td align="center">12</td>
                                 <td align="center">0</td>
                              </tr>
                              <tr>
                                 <td> Coughing</td>
                                 <td align="center">8</td>
                                 <td align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a multicenter, parallel-group, open label postmarketing dosing study consisting of three consecutive 28-day treatment cycles, 220 premenopausal women with secondary amenorrhea were randomized to receive daily conjugated estrogens therapy (0.625 mg conjugated estrogens) and progesterone capsules, 300 mg per day (n = 113) or progesterone capsules, 400 mg per day (n = 107) for 10 days of each treatment cycle. Overall, the most frequently reported treatment-emergent adverse reactions, reported in greater than or equal to 5 percent of subjects, were nausea, fatigue, vaginal mycosis, nasopharyngitis, upper respiratory tract infection, headache, dizziness, breast tenderness, abdominal distension, acne, dysmenorrhea, mood swing, and urinary tract infection.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="2f9d1083-18b1-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Postmarketing Experience:</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been reported with progesterone capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Genitourinary System:</content>endometrial carcinoma, hypospadia, intra-uterine death, menorrhagia, menstrual disorder, metrorrhagia, ovarian cyst, spontaneous abortion.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiovascular:</content>circulatory collapse, congenital heart disease (including ventricular septal defect and patent ductus arteriosus), hypertension, hypotension, tachycardia.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Gastrointestinal:</content>acute pancreatitis, cholestasis, cholestatic hepatitis, dysphagia, hepatic failure, hepatic necrosis, hepatitis, increased liver function tests (including alanine aminotransferase increased, aspartate aminotransferase increased, gamma­-glutamyl transferase increased), jaundice, swollen tongue.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin:</content>alopecia, pruritus, urticaria.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Eyes:</content>blurred vision, diplopia, visual disturbance.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Central Nervous System:</content>aggression, convulsion, depersonalization, depressed consciousness, disorientation, dysarthria, loss of consciousness, paresthesia, sedation, stupor, syncope (with and without hypotension), transient ischemic attack, suicidal ideation.

 </paragraph>
                        <paragraph>During initial therapy, a few women have experienced a constellation of many or all of the following symptoms: extreme dizziness and/or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, feeling drunk, and shortness of breath.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Miscellaneous:</content>abnormal gait, anaphylactic reaction, arthralgia, blood glucose increased, choking, cleft lip, cleft palate, difficulty walking, dyspnea, face edema, feeling abnormal, feeling drunk, hypersensitivity, asthma, muscle cramp, throat tightness, tinnitus, vertigo, weight decreased, weight increased.

 </paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="2f9d1083-18b2-0d45-e063-6394a90ab61d"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>No studies on overdosage have been conducted in humans. In the case of overdosage, progesterone capsules should be discontinued and the patient should be treated symptomatically.</paragraph>
               </text>
               <effectiveTime value="20181128"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="2f9d1083-18b3-0d45-e063-6394a90ab61d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Prevention of Endometrial Hyperplasia</content>
                  </paragraph>
                  <paragraph>Progesterone capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to a postmenopausal woman with a uterus who is receiving daily conjugated estrogens tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Treatment of Secondary Amenorrhea</content>
                  </paragraph>
                  <paragraph>Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days.</paragraph>
                  <paragraph>Some women may experience difficulty swallowing progesterone capsules. For these women, progesterone capsules should be taken with a glass of water while in the standing position.</paragraph>
               </text>
               <effectiveTime value="20240313"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="2f9d1083-18b4-0d45-e063-6394a90ab61d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Progesterone capsules, 100 mg are available as an oval yellow, opaque, capsule imprinted with P-3 in black ink. NDC 69452-233-20 (Bottle of 100)</paragraph>
                  <paragraph>Progesterone capsules, 200 mg are available as an oval white, opaque, capsule imprinted with P-4 in black ink. NDC 69452-234-20 (Bottle of 100)</paragraph>
                  <paragraph>Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]. 
  <br/>
                     <br/>  Protect from excessive moisture.
 </paragraph>
                  <paragraph>Keep out of reach of children.</paragraph>
                  <paragraph>Dispense in tight, light-resistant container as defined in USP/NF, accompanied by a Patient Insert.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Bionpharma Inc</content>
                     <content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>Princeton, NJ 08540, USA</paragraph>
                  <paragraph>
                     <content styleCode="italics">For India Manufacturing Site</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MADE IN INDIA</content>
                  </paragraph>
                  <paragraph>03/2024</paragraph>
               </text>
               <effectiveTime value="20240314"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="2f9d1083-18b5-0d45-e063-6394a90ab61d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules, 100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules, 200 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Read this PATIENT INFORMATION before you start taking progesterone capsules and read what you get each time you refill your progesterone capsules prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
               </text>
               <effectiveTime value="20240313"/>
               <component>
                  <section>
                     <id root="2f9d1083-18b6-0d45-e063-6394a90ab61d"/>
                     <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT PROGESTERONE CAPSULES (A Progesterone Hormone)?</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Progestins with estrogens should not be used to prevent heart disease, heart attacks, strokes, or dementia.</item>
                           <item>Using progestins with estrogens may increase your chance of getting heart attacks, strokes, breast cancer, and blood clots.</item>
                           <item>Using progestins with estrogens may increase your chance of getting dementia, based on a study of women age 65 and older.</item>
                           <item>You and your healthcare provider should talk regularly about whether you still need treatment with progesterone capsules.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.2.1">
                     <id root="2f9d1083-18b7-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">THIS PRODUCT CONTAINS PEANUT OIL AND SHOULD NOT BE USED IF YOU ARE ALLERGIC TO PEANUTS.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">What are progesterone capsules?</content>
                        </paragraph>
                        <paragraph>Progesterone capsules contain the female hormone called progesterone.</paragraph>
                        <paragraph>
                           <content styleCode="bold">What are progesterone capsules used for?</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Treatment of Menstrual Irregularities</content>
                           </content>
                        </paragraph>
                        <paragraph>Progesterone capsules are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period) due to a decrease in progesterone. When you do not produce enough progesterone, menstrual irregularities can occur. If your healthcare provider has determined your body does not produce enough progesterone on its own, progesterone capsules may be prescribed to provide the progesterone you need.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Protection of the Endometrium (Lining of the Uterus)</content>
                           </content>
                        </paragraph>
                        <paragraph>Progesterone capsules are used in combination with estrogen-containing medications in a postmenopausal woman with a uterus (womb). Taking estrogen-alone increases the chance of developing a condition called endometrial hyperplasia that may lead to cancer of the lining of the uterus (womb). The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb).</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.2">
                     <id root="2f9d1083-18b8-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Who should not take progesterone capsules?</title>
                     <text>
                        <paragraph>Do not start taking progesterone capsules if you:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Are allergic to peanuts</content>
                           </item>
                           <item>
                              <content styleCode="bold">Have unusual vaginal bleeding</content>
                           </item>
                           <item>
                              <content styleCode="bold">Currently have or have had certain cancers</content>
                           </item>
                        </list>
                        <paragraph>Estrogen plus progestin treatment may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should take progesterone capsules.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Had a stroke or heart attack</content>
                           </item>
                           <item>
                              <content styleCode="bold">Currently have or have had blood clots</content>
                           </item>
                           <item>
                              <content styleCode="bold">Are allergic to progesterone capsules or any of its ingredients</content>
                           </item>
                        </list>
                        <paragraph>See the list of ingredients in progesterone capsules at the end of this leaflet.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Think you may be pregnant</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Tell your healthcare provider</content>
                           <content styleCode="bold">:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">If you are breastfeeding. </content>The hormone in progesterone capsules can pass into your breast milk.
 
  </item>
                           <item>
                              <content styleCode="bold">About all of your medical problems. </content>Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, problems with your heart, liver, thyroid, or kidneys, or have high calcium levels in your blood.
 
  </item>
                           <item>
                              <content styleCode="bold">About all the medicines you take. </content>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how progesterone capsules work. Progesterone capsules may also affect how your other medicines work.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.3">
                     <id root="2f9d1083-18b9-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>How should I take progesterone capsules?</title>
                     <text>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Prevention of Endometrial Hyperplasia: A postmenopausal woman with a uterus who is taking estrogens should take a single daily dose of 200 mg progesterone capsules at bedtime for 12 continuous days per 28-day cycle.</item>
                           <item>Secondary Amenorrhea: Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days.</item>
                           <item>
                              <content styleCode="bold">Progesterone capsules are to be taken at bedtime as some women become very drowsy and/or dizzy after taking progesterone capsules. In a few cases, symptoms may include blurred vision, difficulty speaking, difficulty with walking, and feeling abnormal. If you experience these symptoms, discuss them with your healthcare provider right away.</content>
                           </item>
                           <item>If you experience difficulty in swallowing progesterone capsules, it is recommended that you take your daily dose at bedtime with a glass of water while in the standing position.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.4">
                     <id root="2f9d1083-18ba-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>What are the possible side effects of progesterone capsules?</title>
                     <text>
                        <paragraph>Side effects are grouped by how serious they are and how often they happen when you are treated:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Serious, but less common side effects include:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="bold">
                                    <content styleCode="italics">Risk to the Fetus: </content>
                                 </content>
                              </content>Cases of cleft palate, cleft lip, hypospadias, ventricular septal defect, patent ductus arteriosus, and other congenital heart defects.
 
  </item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">Abnormal Blood Clotting:</content>
                              </content>Stroke, heart attack, pulmonary embolus, visual loss or blindness.
 
  </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Some of the warning signs of serious side effects include:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Changes in vision or speech</item>
                           <item>Sudden new severe headaches</item>
                           <item>Severe pains in your chest or legs with or without shortness of breath, weakness and fatigue</item>
                           <item>Dizziness and faintness</item>
                           <item>Vomiting</item>
                        </list>
                        <paragraph>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptoms that concern you.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Less serious, but common side effects include:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Headaches</item>
                           <item>Breast pain</item>
                           <item>Irregular vaginal bleeding or spotting</item>
                           <item>Stomach or abdominal cramps, bloating</item>
                           <item>Nausea and vomiting</item>
                           <item>Hair loss</item>
                           <item>Fluid retention</item>
                           <item>Vaginal yeast infection</item>
                        </list>
                        <paragraph>These are not all the possible side effects of progesterone capsules. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects at 1-888-235-2466 or to the FDA at 1-800-FDA-1088 or
 
  <content styleCode="underline">www.fda.gov/medwatch</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.5">
                     <id root="2f9d1083-18bb-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>What can I do to lower my chances of getting a serious side effect with progesterone capsules?</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Talk with your healthcare provider regularly about whether you should continue taking progesterone capsules.</item>
                           <item>See your healthcare provider right away if you get unusual vaginal bleeding while taking progesterone capsules.</item>
                           <item>Have a pelvic exam, breast exam, and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.</item>
                           <item>If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. </item>
                        </list>
                        <paragraph>Ask your healthcare provider for ways to lower your chances for getting heart disease.</paragraph>
                        <paragraph>
                           <content styleCode="bold">General information about safe and effective use of progesterone capsules.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take progesterone capsules for conditions for which it was not prescribed.</item>
                           <item>Your healthcare provider has prescribed this drug for you and you alone. Do not give progesterone capsules to other people, even if they have the same symptoms you have. It may harm them.</item>
                           <item>Progesterone capsules should be taken as a single daily dose at bedtime. Some women may experience extreme dizziness and/or drowsiness during initial therapy. In a few cases, symptoms may include blurred vision, difficulty speaking, difficulty with walking, and feeling abnormal. If you experience these symptoms, discuss them with your healthcare provider right away.</item>
                           <item>Use caution when driving a motor vehicle or operating machinery as dizziness or drowsiness may occur.</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Keep progesterone capsules out of the reach of children.</content>
                        </paragraph>
                        <paragraph>This leaflet provides a summary of the most important information about progesterone capsules. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about progesterone capsules that is written for health professionals. You can get more information by calling the toll free number 1-888-848- 3593.</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.6">
                     <id root="2f9d1083-18bc-0d45-e063-6394a90ab61d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>What are the ingredients in progesterone capsules?</title>
                     <text>
                        <paragraph>Active ingredient: 100 mg or 200 mg micronized progesterone</paragraph>
                        <paragraph>The inactive ingredients for progesterone capsules 100 mg include: ferric oxide yellow, gelatin, glycerin, lecithin, peanut oil, and titanium dioxide.</paragraph>
                        <paragraph>The inactive ingredients for progesterone capsules 200 mg include: gelatin, glycerin, lecithin, peanut oil, and titanium dioxide.</paragraph>
                        <paragraph>
                           <content styleCode="bold">HOW SUPPLIED</content>
                        </paragraph>
                        <paragraph>Progesterone capsules, 100 mg are available as an oval yellow, opaque, capsule imprinted with P-3 in black ink. NDC 69452-233-20 (Bottle of 100 capsules)</paragraph>
                        <paragraph>Progesterone capsules, 200 mg are available as an oval white, opaque, capsule imprinted with P-4 in black ink. NDC 69452-234-20 (Bottle of 100 capsules)</paragraph>
                        <paragraph>
                           <content styleCode="bold">Store at 20-25°C (68-77°F)</content>
                        </paragraph>
                        <paragraph>Protect from excessive moisture.</paragraph>
                        <paragraph>Manufactured for:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Bionpharma Inc.</content>
                        </paragraph>
                        <paragraph>Princeton, NJ 08540, USA</paragraph>
                        <paragraph>
                           <content styleCode="italics">For India Manufacturing Site</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">MADE IN INDIA</content>
                        </paragraph>
                        <paragraph>03/24</paragraph>
                     </text>
                     <effectiveTime value="20240313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="2f9d1083-18bd-0d45-e063-6394a90ab61d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label (US Site)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 69452-233-20</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DO NOT USE IF ALLERGIC TO PEANUTS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: PLEASE DISPENSE WITH ACCOMPANYING PATIENT INFORMATION LEAFLET</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Count Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BIONPHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L6f37f25d-de46-40b8-ae72-08a5268caf41"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <observationMedia ID="L6f37f25d-de46-40b8-ae72-08a5268caf41">
                     <text>100 mg Capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="progesterone-image01-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc7fb89b0-fdbe-4a20-a558-301224645a1e">
               <id root="2f9d1083-18be-0d45-e063-6394a90ab61d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label (India Site)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 69452-233-20</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DO NOT USE IF ALLERGIC TO PEANUTS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: PLEASE DISPENSE WITH ACCOMPANYING PATIENT INFORMATION LEAFLET</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Count Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BIONPHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L6759d7d2-1290-4b93-930d-5107075842e0"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <observationMedia ID="L6759d7d2-1290-4b93-930d-5107075842e0">
                     <text>100 mg Capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="progesterone-image01-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="2f9d1083-18bf-0d45-e063-6394a90ab61d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label (US Site)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 69452-234-20</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DO NOT USE IF ALLERGIC TO PEANUTS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: PLEASE DISPENSE WITH ACCOMPANYING PATIENT INFORMATION LEAFLET</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Count Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BIONPHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L959c55d5-c458-46c1-b18e-be20d887c2b5"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <observationMedia ID="L959c55d5-c458-46c1-b18e-be20d887c2b5">
                     <text>200 mg Capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="progesterone-image02-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lde987b28-aa97-45c7-9efc-2307e1ea30bd">
               <id root="2f9d1083-18c0-0d45-e063-6394a90ab61d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label (India Site)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 69452-234-20</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Progesterone Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DO NOT USE IF ALLERGIC TO PEANUTS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST: PLEASE DISPENSE WITH ACCOMPANYING PATIENT INFORMATION LEAFLET</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Count Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BIONPHARMA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L02fd48bc-4e8e-4ac1-b1e0-069201680e8c"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240314"/>
               <component>
                  <observationMedia ID="L02fd48bc-4e8e-4ac1-b1e0-069201680e8c">
                     <text>200 mg Capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="progesterone-image02-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>